I-Mab (NASDAQ:IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel biologics to treat cancer and autoimmune disorders. Founded in 2016 and headquartered in Shanghai, China with U.S. operations in Rockville, Maryland, the company applies its proprietary immunology platforms to identify and advance first-in-class and best-in-class antibody therapies. I-Mab’s research capabilities span antibody engineering, translational biology and process development, supporting a broad pipeline of drug candidates targeting the immune system.
The company’s pipeline includes multiple monoclonal antibody therapies in various stages of clinical development. Key programs address immune-oncology indications, with agents designed to modulate immune checkpoints and enhance anti-tumor responses. In parallel, I-Mab is advancing antibodies for autoimmune diseases, aiming to restore immune balance in conditions such as rheumatoid arthritis and systemic lupus erythematosus. Its development strategy encompasses single-agent and combination regimens, reflecting the company’s commitment to creating differentiated therapies.
I-Mab serves global markets through strategic collaborations and partnerships with multinational biopharmaceutical firms. The company leverages its dual presence in China and the United States to facilitate cross-border clinical trials and regulatory engagements. By combining insights from both regions, I-Mab aims to accelerate patient access to its therapeutic candidates and address unmet medical needs in diverse patient populations.
The leadership team at I-Mab brings together experienced executives in biotechnology R&D, clinical development and regulatory affairs. Guided by a board of directors with deep industry expertise, the company has established a robust governance framework to support its growth. As it advances its pipeline through late-stage studies, I-Mab remains focused on delivering innovative biologics that harness the power of the immune system for patients worldwide.
